SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
04 11 2021
Historique:
pubmed: 5 11 2021
medline: 25 11 2021
entrez: 4 11 2021
Statut: epublish

Résumé

The SARS-CoV-2 virus is rapidly evolving via mutagenesis, lengthening the pandemic, and threatening the public health. Until August 2021, 12 variants of SARS-CoV-2 named as variants of concern (VOC; Alpha to Delta) or variants of interest (VOI; Epsilon to Mu), with significant impact on transmissibility, morbidity, possible reinfection and mortality, have been identified. The VOC Delta (B.1.617.2) of Indian origin is now the dominant and the most contagious variant worldwide as it provokes a strong binding to the human ACE2 receptor, increases transmissibility and manifests considerable immune escape strategies after natural infection or vaccination. Although the development and administration of SARS-CoV-2 vaccines, based on different technologies (mRNA, adenovirus carrier, recombinant protein, etc.), are very promising for the control of the pandemic, their effectiveness and neutralizing activity against VOCs varies significantly. In this review, we describe the most significant circulating variants of SARS-CoV-2, and the known effectiveness of currently available vaccines against them.

Identifiants

pubmed: 34732275
doi: 10.1017/S0950268821002430
pii: S0950268821002430
pmc: PMC8632374
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e237

Références

Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA. 2021 Jul 6;326(1):35-45
pubmed: 34037666
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Mem Inst Oswaldo Cruz. 2020 Sep 25;115:e200310
pubmed: 32997001
Lancet. 2021 Jul 17;398(10296):207-209
pubmed: 34197809
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Sep 8;324(10):951-960
pubmed: 32789505
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Infect Genet Evol. 2021 Nov;95:105038
pubmed: 34403832
Infez Med. 2020 Ahead of print Jun 1;28(2):174-184
pubmed: 32275259
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
Vaccine. 2021 Sep 24;39(40):5963-5967
pubmed: 34400017
N Engl J Med. 2021 Jul 8;385(2):179-186
pubmed: 34161052
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
N Engl J Med. 2021 Aug 12;385(7):664-666
pubmed: 34233096
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34002240
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Nature. 2021 Jan 29;:
pubmed: 33526898
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Int J Mol Sci. 2021 Jul 10;22(14):
pubmed: 34299045
Clin Transl Immunology. 2021 Feb 22;10(2):e1241
pubmed: 33628442
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
N Engl J Med. 2021 Jun 17;384(24):2352-2354
pubmed: 33826819
Clin Infect Dis. 2022 Jan 29;74(2):366-368
pubmed: 33961693
N Engl J Med. 2020 Feb 20;382(8):760-762
pubmed: 31978944
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Lancet Infect Dis. 2021 May;21(5):637-646
pubmed: 33485468
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
J Med Virol. 2021 Dec;93(12):6828-6832
pubmed: 34314048
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Nature. 2021 Apr;592(7852):122-127
pubmed: 33636719
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
J Mol Biol. 2020 Sep 4;432(19):5212-5226
pubmed: 32710986
Clin Infect Dis. 2022 May 3;74(9):1623-1630
pubmed: 34309648
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Autoimmun. 2021 Nov;124:102715
pubmed: 34399188
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Lancet Infect Dis. 2021 Aug;21(8):1071-1072
pubmed: 34051887
MMWR Morb Mortal Wkly Rep. 2021 Jul 27;70(30):1044-1047
pubmed: 34324480
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Emerg Infect Dis. 2021 May;27(5):1522-1524
pubmed: 33605869
Viruses. 2021 Jun 23;13(7):
pubmed: 34201767
J Basic Microbiol. 2021 Mar;61(3):180-202
pubmed: 33460172
R I Med J (2013). 2021 Sep 1;104(7):59-60
pubmed: 34339484
mBio. 2021 Aug 31;12(4):e0138621
pubmed: 34311587
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
J Med Virol. 2021 Dec;93(12):6468-6470
pubmed: 34329486
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
BMJ. 2021 Apr 9;373:n912
pubmed: 33836994
J Travel Med. 2021 Dec 29;28(8):
pubmed: 34581415
J Mol Biol. 2021 Sep 3;433(18):167155
pubmed: 34273397
Nat Commun. 2021 Jul 26;12(1):4598
pubmed: 34312390
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4
pubmed: 33306985
Nature. 2021 Feb;590(7844):17
pubmed: 33510489
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Lancet Infect Dis. 2021 Sep;21(9):1246-1256
pubmed: 33857406
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
J Infect Dis. 2021 Mar 3;223(5):802-804
pubmed: 33257936
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211024372
pubmed: 34211709
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Nat Commun. 2021 Nov 9;12(1):6563
pubmed: 34753934
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9436-41
pubmed: 26159422
Genomics. 2021 Jul;113(4):2158-2170
pubmed: 34004284
Pathogens. 2021 May 21;10(6):
pubmed: 34064143
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Science. 2005 Oct 28;310(5748):676-9
pubmed: 16195424
BMJ Open Respir Res. 2021 Sep;8(1):
pubmed: 34544733
MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):712-716
pubmed: 33983915

Auteurs

Elizabeth-Barbara Tatsi (EB)

First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527Athens, Greece.

Filippos Filippatos (F)

First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527Athens, Greece.

Athanasios Michos (A)

First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH